Multivariable models for mortality, relapse, transplant-related mortality, and chronic GVHD
| Variable . | Hazard ratio (95% confidence interval; P) . | ||||
|---|---|---|---|---|---|
| Mortality . | Relapse . | Transplant-related mortality . | Chronic GVHD . | ||
| HLA-B leader | Match | 1.0 | — | 1.0 | — |
| Mismatch | 1.24 (1.08-1.43; .003) | — | 1.43 (1.13-1.82; .003) | — | |
| HLA-DPB1 | TCE match or permissive | 1.0 (P = .006) | — | — | — |
| TCE nonpermissive | 0.59 (0.43-0.82; .002) | — | — | — | |
| Missing | 0.92 (0.81-1.06; .26) | — | — | — | |
| HLA-DRB1 | Match/HVG mismatch | — | 1 | — | — |
| GVH mismatch | — | 0.65 (0.53-0.80; <.0001) | — | — | |
| HLA-C | Match | — | — | — | 1.0 |
| Mismatch | — | — | — | 1.46 (1.17-1.83; .0008) | |
| Recipient HLA-C MFI (by 10 increment) | 1.04 (1.02-1.07; .0003) | ||||
| Donor age (y) | <20 | 1.0 (P = .05) | — | — | — |
| 20-29 | 1.32 (0.94-1.85; .11) | — | — | — | |
| 30-39 | 1.35 (0.97-1.87; .07) | — | — | — | |
| 40-49 | 1.52 (1.06-2.18; .02) | — | — | — | |
| 50-59 | 1.62 (1.13-2.32; .008) | — | — | — | |
| Disease type | AML | 1.0 (P = .085) | |||
| ALL | 1.33 (1.03-1.71; .03) | ||||
| MDS | 0.98 (0.66-1.44; .90) | ||||
| Disease/stage | AML/CR1 | 1.0 (P < .0001) | — | 1.0 (P < .0001) | |
| AML/CR2, CR3 | 1.10 (0.76-1.60; .60) | — | 0.72 (0.38-1.35; .30) | ||
| AML/advanced | 2.10 (1.60-2.75; <.0001) | — | 2.04 (1.44-2.88; .0001) | ||
| ALL/CR1 | 0.56 (0.41-0.76; .0002) | — | 0.66 (0.42-1.03; .07) | ||
| ALL/CR2 | 1.59 (1.04-2.43; .03) | — | 1.17 (0.59-2.32; .65) | ||
| ALL/≥CR3 | 2.51 (1.60-3.93; .0001) | — | 1.95 (0.73-5.25; .18) | ||
| MDS/early | 1.22 (0.85-1.76; .28) | — | 0.70 (0.36-1.35; .29) | ||
| MDS/advanced | 1.33 (1.05-1.68; .02) | — | 1.51 (1.10-2.06; .10) | ||
| Donor/patient CMV serostatus | Positive/positive | 1.0 (P = .001) | — | 1.0 (P = .0001) | — |
| Positive/negative | 0.93 (0.71-1.22; .59) | — | 1.22 (0.78-1.91; .39) | — | |
| Negative/positive | 0.96 (0.79-1.16; .67) | — | 0.75 (0.54-1.05; .10) | — | |
| Negative/negative | 0.68 (0.53-0.86; .001) | — | 0.50 (0.32-0.78; .002) | — | |
| Missing | 1.53 (0.78-3.03; .22) | — | 1.66 (0.70-3.90; .25) | — | |
| Time from diagnosis to transplant (mos). | ≤6 | 1.0 (P = .04) | 1.0 (P = .0003) | — | 1.0 (P = .0004) |
| 6-12 | 1.06 (0.83-1.36; .64) | 0.84 (0.70-1.00; .04) | — | 0.97 (0.75-1.25; .79) | |
| 12-24 | 0.85 (0.66-1.10; .21) | 0.54 (0.39-0.75; .0003) | — | 1.44 (1.14-1.81; .002) | |
| >24 | 0.69 (0.48-0.98; .04) | 0.39 (0.24-0.64; .0002) | — | 1.41 (1.09-1.82; .009) | |
| HCT comorbidity index | 0 | 1.0 (P = .0006) | — | 1.0 (P = .003) | — |
| 1 | 1.29 (0.99-1.67; .06) | — | 1.54 (0.96-2.46; .07) | — | |
| 2 | 1.42 (1.09-1.84; .009) | — | 1.84 (1.17-2.89; .008) | — | |
| ≥3 | 1.68 (1.30-2.18; .0001) | — | 2.19 (1.43-3.34; .0003) | — | |
| Donor/patient sex | Male/male | — | — | — | 1.0 (P = .09) |
| Male/female | — | — | — | 1.28 (0.95-1.72; .11) | |
| Female/male | — | — | — | 1.36 (1.06-1.74; .02) | |
| Female/female | — | — | — | 1.33 (0.99-1.79; .05) | |
| Patient Age (y) | 1-18 | 1.0 (P < .0001) | — | 1.0 (P < .0001) | 1.0 (P = .02) |
| 19-29 | 0.81 (0.53-1.24; .33) | — | 1.18 (0.58-2.41; .65) | 0.84 (0.50-1.41; .50) | |
| 30-39 | 0.77 (0.53-1.11; .16) | — | 0.88 (0.40-1.92; .74) | 0.77 (0.42-1.39; .38) | |
| 40-49 | 0.80 (0.54-1.20; .29) | — | 1.29 (0.57-2.94; .54) | 1.20 (0.71-2.03; .49) | |
| 50-59 | 1.05 (0.72-1.52; .80) | — | 1.77 (0.78-4.01; .17) | 0.83 (0.48-1.46; .53) | |
| ≥60 | 1.34 (0.90-2.00; .15) | — | 2.88 (1.34-6.17; .007) | 0.77 (0.43-1.38; .39) | |
| Conditioning regimen | Myeloablative | — | 1.0 | 1.0 | — |
| Reduced intensity/nonmyeloablative | — | 1.57 (1.33-1.86; <.0001) | 0.72 (0.54-0.96; .03) | — | |
| Graft source | Marrow | — | — | — | 1.0 |
| Peripheral blood stem cells | — | — | — | 2.33 (1.61-3.37; <.0001) | |
| Variable . | Hazard ratio (95% confidence interval; P) . | ||||
|---|---|---|---|---|---|
| Mortality . | Relapse . | Transplant-related mortality . | Chronic GVHD . | ||
| HLA-B leader | Match | 1.0 | — | 1.0 | — |
| Mismatch | 1.24 (1.08-1.43; .003) | — | 1.43 (1.13-1.82; .003) | — | |
| HLA-DPB1 | TCE match or permissive | 1.0 (P = .006) | — | — | — |
| TCE nonpermissive | 0.59 (0.43-0.82; .002) | — | — | — | |
| Missing | 0.92 (0.81-1.06; .26) | — | — | — | |
| HLA-DRB1 | Match/HVG mismatch | — | 1 | — | — |
| GVH mismatch | — | 0.65 (0.53-0.80; <.0001) | — | — | |
| HLA-C | Match | — | — | — | 1.0 |
| Mismatch | — | — | — | 1.46 (1.17-1.83; .0008) | |
| Recipient HLA-C MFI (by 10 increment) | 1.04 (1.02-1.07; .0003) | ||||
| Donor age (y) | <20 | 1.0 (P = .05) | — | — | — |
| 20-29 | 1.32 (0.94-1.85; .11) | — | — | — | |
| 30-39 | 1.35 (0.97-1.87; .07) | — | — | — | |
| 40-49 | 1.52 (1.06-2.18; .02) | — | — | — | |
| 50-59 | 1.62 (1.13-2.32; .008) | — | — | — | |
| Disease type | AML | 1.0 (P = .085) | |||
| ALL | 1.33 (1.03-1.71; .03) | ||||
| MDS | 0.98 (0.66-1.44; .90) | ||||
| Disease/stage | AML/CR1 | 1.0 (P < .0001) | — | 1.0 (P < .0001) | |
| AML/CR2, CR3 | 1.10 (0.76-1.60; .60) | — | 0.72 (0.38-1.35; .30) | ||
| AML/advanced | 2.10 (1.60-2.75; <.0001) | — | 2.04 (1.44-2.88; .0001) | ||
| ALL/CR1 | 0.56 (0.41-0.76; .0002) | — | 0.66 (0.42-1.03; .07) | ||
| ALL/CR2 | 1.59 (1.04-2.43; .03) | — | 1.17 (0.59-2.32; .65) | ||
| ALL/≥CR3 | 2.51 (1.60-3.93; .0001) | — | 1.95 (0.73-5.25; .18) | ||
| MDS/early | 1.22 (0.85-1.76; .28) | — | 0.70 (0.36-1.35; .29) | ||
| MDS/advanced | 1.33 (1.05-1.68; .02) | — | 1.51 (1.10-2.06; .10) | ||
| Donor/patient CMV serostatus | Positive/positive | 1.0 (P = .001) | — | 1.0 (P = .0001) | — |
| Positive/negative | 0.93 (0.71-1.22; .59) | — | 1.22 (0.78-1.91; .39) | — | |
| Negative/positive | 0.96 (0.79-1.16; .67) | — | 0.75 (0.54-1.05; .10) | — | |
| Negative/negative | 0.68 (0.53-0.86; .001) | — | 0.50 (0.32-0.78; .002) | — | |
| Missing | 1.53 (0.78-3.03; .22) | — | 1.66 (0.70-3.90; .25) | — | |
| Time from diagnosis to transplant (mos). | ≤6 | 1.0 (P = .04) | 1.0 (P = .0003) | — | 1.0 (P = .0004) |
| 6-12 | 1.06 (0.83-1.36; .64) | 0.84 (0.70-1.00; .04) | — | 0.97 (0.75-1.25; .79) | |
| 12-24 | 0.85 (0.66-1.10; .21) | 0.54 (0.39-0.75; .0003) | — | 1.44 (1.14-1.81; .002) | |
| >24 | 0.69 (0.48-0.98; .04) | 0.39 (0.24-0.64; .0002) | — | 1.41 (1.09-1.82; .009) | |
| HCT comorbidity index | 0 | 1.0 (P = .0006) | — | 1.0 (P = .003) | — |
| 1 | 1.29 (0.99-1.67; .06) | — | 1.54 (0.96-2.46; .07) | — | |
| 2 | 1.42 (1.09-1.84; .009) | — | 1.84 (1.17-2.89; .008) | — | |
| ≥3 | 1.68 (1.30-2.18; .0001) | — | 2.19 (1.43-3.34; .0003) | — | |
| Donor/patient sex | Male/male | — | — | — | 1.0 (P = .09) |
| Male/female | — | — | — | 1.28 (0.95-1.72; .11) | |
| Female/male | — | — | — | 1.36 (1.06-1.74; .02) | |
| Female/female | — | — | — | 1.33 (0.99-1.79; .05) | |
| Patient Age (y) | 1-18 | 1.0 (P < .0001) | — | 1.0 (P < .0001) | 1.0 (P = .02) |
| 19-29 | 0.81 (0.53-1.24; .33) | — | 1.18 (0.58-2.41; .65) | 0.84 (0.50-1.41; .50) | |
| 30-39 | 0.77 (0.53-1.11; .16) | — | 0.88 (0.40-1.92; .74) | 0.77 (0.42-1.39; .38) | |
| 40-49 | 0.80 (0.54-1.20; .29) | — | 1.29 (0.57-2.94; .54) | 1.20 (0.71-2.03; .49) | |
| 50-59 | 1.05 (0.72-1.52; .80) | — | 1.77 (0.78-4.01; .17) | 0.83 (0.48-1.46; .53) | |
| ≥60 | 1.34 (0.90-2.00; .15) | — | 2.88 (1.34-6.17; .007) | 0.77 (0.43-1.38; .39) | |
| Conditioning regimen | Myeloablative | — | 1.0 | 1.0 | — |
| Reduced intensity/nonmyeloablative | — | 1.57 (1.33-1.86; <.0001) | 0.72 (0.54-0.96; .03) | — | |
| Graft source | Marrow | — | — | — | 1.0 |
| Peripheral blood stem cells | — | — | — | 2.33 (1.61-3.37; <.0001) | |
The model for mortality is stratified by graft source, and the model for relapse is stratified by disease type and stage. P values in reference group rows represent the whole group comparison for the variable of interest on the designated outcome.
AML, acute myeloid leukemia; ALL, acute lymphoblastic leukemia; MDS, myelodysplastic syndrome; CR, complete remission.